Radiation exposure of young patients with abdominal neuroblastoma from therapeutic and imaging procedures: a phantom study
- PMID: 40694233
- DOI: 10.1007/s13246-025-01601-6
Radiation exposure of young patients with abdominal neuroblastoma from therapeutic and imaging procedures: a phantom study
Abstract
This study calculated the radiation dose to young patients with high-risk abdominal neuroblastoma from therapeutic and imaging procedures. Computational XCAT phantoms representing typical patients aged 5-15 years were used. Intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) plans were generated with 6 MV photons for a planning target volume (PTV) on the left and right abdominal side. Dose-volume-histograms from the plans were used to find the average dose (Dav) to critical normal abdominal and thoracic organs. The imaging dose to these organs and PTV was calculated by simulating kV cone-beam computed tomography (CBCT) scanning for patient setup before radiotherapy. Different CBCT protocols were simulated with Monte Carlo methods. The IMRT and VMAT plans provided similar PTV coverage and organ sparing. For a 21.6 Gy target dose, the Dav of the abdominal organs from the treatment plans was 3.6-19.6 Gy and that of thoracic organs was 0.1-2.3 Gy. Daily CBCT scans on 15-year-old patients with the standard adult protocol gave total PTV and organ doses of 95.3-485.3 mGy. The doses from the modified standard protocol for 5- and 10-year-old patients were 74.2-159.6 mGy. The dose calculations with a specially designed CBCT protocol for patients up to 10 years were 6.0-27.8 mGy. The total imaging dose to the PTV was up to 2.2% of the delivered therapeutic dose. The replacement of the modified adult CBCT protocol with a special protocol solely defined for children reduced the radiation dose to target and normal organs by more than five times.
Keywords: CBCT; Imaging dose; Neuroblastoma; Organ doses; Radiation therapy.
© 2025. Australasian College of Physical Scientists and Engineers in Medicine.
Conflict of interest statement
Declarations. Conflict of interests: The authors have no relevant financial or non-financial interests to disclose. Ethical approval: The study did not involve human or animal subjects. Consent to participate: The study did not involve human subjects. Consent for publication: The study did not involve human subjects.
Similar articles
-
Evaluation of volumetric modulated arc therapy dose calculation plans based on kV-cone beam CT images for the breast cancer treatment.Phys Eng Sci Med. 2025 Jul 21. doi: 10.1007/s13246-025-01592-4. Online ahead of print. Phys Eng Sci Med. 2025. PMID: 40690179
-
Intensity-modulated Radiotherapy Versus Volumetric Modulated Arc Therapy in Head and Neck Cancers: A Comparative Analysis of Compliance, Toxicities and Dosimetric Parameters.Cureus. 2025 Jun 16;17(6):e86143. doi: 10.7759/cureus.86143. eCollection 2025 Jun. Cureus. 2025. PMID: 40672034 Free PMC article.
-
Evaluation of Concomitant Imaging Dose in 4D-CBCT Guided Thoracic Radiotherapy.Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251366729. doi: 10.1177/15330338251366729. Epub 2025 Aug 6. Technol Cancer Res Treat. 2025. PMID: 40770953 Free PMC article.
-
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD009263. doi: 10.1002/14651858.CD009263.pub2. Cochrane Database Syst Rev. 2015. PMID: 26417712 Free PMC article.
-
Dosimetric comparison between Intensity Modulated Radiation Therapy (IMRT) vs dual arc Volumetric Arc Therapy (VMAT) for nasopharyngeal cancer (NPC): Systematic review and meta-analysis.J Med Imaging Radiat Sci. 2023 Mar;54(1):167-177. doi: 10.1016/j.jmir.2022.10.195. Epub 2022 Nov 29. J Med Imaging Radiat Sci. 2023. PMID: 36456460
References
-
- Paulino AC, Mahajan A (2019) Neuroblastoma. In: Halperin EC, Wazer DE, Perez CA, Brady LW (eds) Principles and practice of radiation oncology, 7th edn. Wolters Kluver, Philadelphia, pp 2017–2027
-
- Ward E, DeSantis C, Robbins A, Kohler B, Jemal A (2014) Childhood and adolescent cancer statistics, 2014. Ca Cancer J Clin 64:83–103 - PubMed
-
- National Comprehensive Cancer Network (NCCN) (2024) NCCN Clinical Practice Guidelines in Oncology, Neuroblastoma. Available at http://www.nccn.org . Accessed 17 February 2025
-
- DuBois SG, Macy ME, Henderson TO (2022) High-risk and relapsed neuroblastoma: toward more cures and better outcomes. Am Soc Clin Oncol Educ Book 42:1–13 - PubMed